Supplementary File for: An imperfect tool: COVID-19 'test & trace' success relies on minimising the impact of false negatives and continuation of physical distancing.

Emma L. Davis^{1,+,*}, Tim C. D. Lucas^{1,+}, Anna Borlase¹, Timothy M Pollington^{1,3}, Sam Abbott², Diepreye Ayabina¹, Thomas Crellen¹, Joel Hellewell², Li Pi¹, CMMID COVID-19 working group¹, Graham F. Medley⁴, T. Déirdre Hollingsworth^{1,†}, and Petra Klepac^{2,5,†}

¹Big Data Institute, University of Oxford, UK.
²Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, UK.
³MathSys CDT, University of Warwick, UK.
⁴Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene and Tropical Medicine, London, UK.
⁵Department for Applied Mathematics and Theoretical Physics, University of Cambridge, UK.
*Corresponding author +,[†]Contributed equally

1 Additional figures




Figure S1: Comparing testing procedures. Comparing utility of testand-release of negative-testing cases (left-hand panels) with maintaining isolation of cases for a minimum of 7 days (right-hand panels) given assumed test sensitivities of 65% or 95%, and compared to no-testing. R_S is assumed to be 1.3. Error bars: 95% confidence intervals calculated from simulation output variation.

² CMMID working group authorship list

³ The following authors were part of the Centre for Mathematical Modelling of

⁴ Infectious Disease 2019-nCoV working group. Each contributed in process-

⁵ ing, cleaning and interpretation of data, interpreted findings, contributed

to the manuscript, and approved the work for publication: Alicia Rosello, 6 Rosalind M Eggo, Quentin J Leclerc, Matthew Quaife, Emily S Nightin-7 gale, Thibaut Jombart, Jon C Emery, Timothy W Russell, Nikos I Bosse, 8 Megan Auzenbergs, Amy Gimma, Charlie Diamond, Yang Liu, Kiesha Prem, 9 Eleanor M Rees, Christopher I Jarvis, W John Edmunds, Akira Endo, David 10 Simons, Billy J Quilty, Damien C Tully, Oliver Brady, C Julian Villabona-11 Arenas, Gwenan M Knight, Samuel Clifford, Stéphane Hué, Kevin van Zand-12 voort, Adam J Kucharski, Mark Jit, Arminder K Deol, Kathleen O'Reilly, 13 Anna M Foss, Fiona Yueqian Sun, James D Munday, Hamish P Gibbs, Rein 14 M G J Houben, Rachel Lowe, Sophie R Meakin, Georgia R Gore-Langton, 15 Sebastian Funk, Carl A B Pearson, Katherine E. Atkins, Simon R Procter, 16 Stefan Flasche, Nicholas G. Davies. 17

The following funding sources are acknowledged as providing funding 18 for the working group authors. Alan Turing Institute (AE). BBSRC LIDP 19 (BB/M009513/1: DS). This research was partly funded by the Bill & Melinda 20 Gates Foundation (INV-003174: KP, MJ, YL; NTD Modelling Consortium 21 OPP1184344: CABP; OPP1180644: SRP; OPP1183986: ESN; OPP1191821: 22 KO'R, MA). DFID/Wellcome Trust (Epidemic Preparedness Coronavirus re-23 search programme 221303/Z/20/Z: CABP, KvZ). Elrha R2HC/UK DFID/ 24 Wellcome Trust/This research was partly funded by the National Institute 25 for Health Research (NIHR) using UK aid from the UK Government to sup-26 port global health research. The views expressed in this publication are 27 those of the author(s) and not necessarily those of the NIHR or the UK De-28 partment of Health and Social Care (KvZ). ERC Starting Grant (#757688: 29 CJVA, KEA; #757699: JCE, MQ, RMGJH). This project has received fund-30 ing from the European Union's Horizon 2020 research and innovation pro-31 gramme - project EpiPose (101003688: KP, MJ, WJE, YL). This research 32 was partly funded by the Global Challenges Research Fund (GCRF) project 33 'RECAP' managed through RCUK and ESRC (ES/P010873/1: AG, CIJ, 34 TJ). HDR UK (MR/S003975/1: RME). Nakajima Foundation (AE). NIHR 35 (16/137/109: BJQ, CD, FYS, MJ, YL; Health Protection Research Unit for 36 Modelling Methodology HPRU-2012-10096: NGD, TJ; PR-OD-1017-20002: 37 AR). Royal Society (Dorothy Hodgkin Fellowship: RL). UK DHSC/UK 38 Aid/NIHR (ITCRZ 03010: HPG). UK MRC (LID DTP MR/N013638/1: 39 EMR, GRGL, QJL; MC_PC 19065: RME; MR/P014658/1: GMK). Au-40 thors of this research receive funding from UK Public Health Rapid Support 41 Team funded by the United Kingdom Department of Health and Social Care 42 (TJ). Wellcome Trust (206250/Z/17/Z: AJK, TWR; 206471/Z/17/Z: OJB; 43

- $_{\rm 44}$ 208812/Z/17/Z: SC, SFlasche; 210758/Z/18/Z: JDM, NIB, SFunk, SRM).
- ⁴⁵ No funding (AKD, AMF, DCT, SH).